101 related articles for article (PubMed ID: 22551782)
1. [Short and medium term cardiotoxicity of anthracyclins: a prospective study].
Elalouani C; Benhmidoun MA; Rida H; AitRaiss M; Derhem N; Elomrani A; Khouchani M; Tahri A; Errehmouni A; Faouzi R; Elguenzri A; Elhattaoui M; Tazi I; Mahmal L
Ann Cardiol Angeiol (Paris); 2012 Aug; 61(4):257-66. PubMed ID: 22551782
[TBL] [Abstract][Full Text] [Related]
2. Early Changes in Myocardial Mechanics Detected by 3-Dimensional Speckle Tracking Echocardiography in Patients Treated With Low Doses of Anthracyclines.
Piveta RB; Rodrigues ACT; Vieira MLC; Fischer CH; Afonso TR; Daminello E; Cruz FM; Galvão TFG; Katz M; Morhy SS
JACC Cardiovasc Imaging; 2018 Nov; 11(11):1729-1731. PubMed ID: 29909102
[No Abstract] [Full Text] [Related]
3. Left ventricular systolic function in HER2/neu negative breast cancer patients treated with anthracycline chemotherapy: a comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months.
Stoodley PW; Richards DA; Boyd A; Hui R; Harnett PR; Meikle SR; Byth K; Stuart K; Clarke JL; Thomas L
Eur J Cancer; 2013 Nov; 49(16):3396-403. PubMed ID: 23937961
[TBL] [Abstract][Full Text] [Related]
4. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
5. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
6. Early detection of epirubicin-induced cardiotoxicity in patients with breast cancer.
Florescu M; Magda LS; Enescu OA; Jinga D; Vinereanu D
J Am Soc Echocardiogr; 2014 Jan; 27(1):83-92. PubMed ID: 24268372
[TBL] [Abstract][Full Text] [Related]
7. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.
Hayakawa H; Komada Y; Hirayama M; Hori H; Ito M; Sakurai M
Med Pediatr Oncol; 2001 Jul; 37(1):4-9. PubMed ID: 11466716
[TBL] [Abstract][Full Text] [Related]
8. Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up.
Murtagh G; Lyons T; O'Connell E; Ballot J; Geraghty L; Fennelly D; Gullo G; Ledwidge M; Crown J; Gallagher J; Watson C; McDonald KM; Walshe JM
Breast Cancer Res Treat; 2016 Apr; 156(3):501-506. PubMed ID: 27060913
[TBL] [Abstract][Full Text] [Related]
9. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
Villani F; Meazza R; Materazzo C
Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
[TBL] [Abstract][Full Text] [Related]
10. Late cardiotoxicity after treatment for a malignant bone tumor.
Postma A; Bink-Boelkens MT; Beaufort-Krol GC; Kengen RA; Elzenga NJ; Schasfoort-van Leeuwen MJ; Schraffordt koops H; Kamps WA
Med Pediatr Oncol; 1996 Apr; 26(4):230-7. PubMed ID: 8600333
[TBL] [Abstract][Full Text] [Related]
11. Tissue-Doppler assessment of cardiac left ventricular function during short-term adjuvant epirubicin therapy for breast cancer.
Appel JM; Sogaard P; Mortensen CE; Skagen K; Nielsen DL
J Am Soc Echocardiogr; 2011 Feb; 24(2):200-6. PubMed ID: 21227647
[TBL] [Abstract][Full Text] [Related]
12. Comparison of epirubicin and doxorubicin cardiotoxicity in children and adolescents treated within the German Cooperative Soft Tissue Sarcoma Study (CWS).
Stöhr W; Paulides M; Brecht I; Kremers A; Treuner J; Langer T; Beck JD;
J Cancer Res Clin Oncol; 2006 Jan; 132(1):35-40. PubMed ID: 16205946
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M
Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181
[TBL] [Abstract][Full Text] [Related]
14. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
15. Two-dimensional speckle tracking echocardiography combined with high-sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine-based chemotherapy.
Kang Y; Xu X; Cheng L; Li L; Sun M; Chen H; Pan C; Shu X
Eur J Heart Fail; 2014 Mar; 16(3):300-8. PubMed ID: 24464946
[TBL] [Abstract][Full Text] [Related]
16. Regional cardiac wall motion abnormalities during and shortly after anthracyclines therapy.
Kapusta L; Groot-Loonen J; Thijssen JM; DeGraaf R; Daniëls O
Med Pediatr Oncol; 2003 Nov; 41(5):426-35. PubMed ID: 14515381
[TBL] [Abstract][Full Text] [Related]
17. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
18. Familial dilated cardiomyopathy: another risk factor for anthracycline-induced cardiotoxicity?
van den Berg MP; van Spaendonck-Zwarts KY; van Veldhuisen DJ; Gietema JA; Postma A; van Tintelen JP
Eur J Heart Fail; 2010 Dec; 12(12):1297-9. PubMed ID: 20952769
[No Abstract] [Full Text] [Related]
19. Identification of anthracycline cardiotoxicity: left ventricular ejection fraction is not enough.
Eidem BW
J Am Soc Echocardiogr; 2008 Dec; 21(12):1290-2. PubMed ID: 19041570
[No Abstract] [Full Text] [Related]
20. The evaluation of left ventricular function in childhood cancer survivors by pharmacological stress echocardiography.
Elbl L; Hrstkova H; Chaloupka V; Novotny J; Michalek J
Neoplasma; 2003; 50(3):191-7. PubMed ID: 12937852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
